Rheumatoid Arthritis
Conditions
Keywords
Anti-inflammatory diet, Disease activity, Quality of life, Rheumatoid arthritis
Brief summary
Rheumatoid arthritis (RA) is an autoimmune disease that affects 0.5-1% of the population and in which his remission is not always achieved, affecting physical and mental well-being and quality of life (QL). As a complement to pharmacotherapy, dietary intervention should be evaluated as a treatment option. The main objective of this parallel controlled randomized clinical trial is to check the effect of an anti-inflammatory dietary intervention, compared to a diet based on the principles of the Mediterranean diet (control), on disease activity (AD) and improving QL. Patients will be instructed to follow an anti-inflammatory diet (DAI) or a control diet (DC) for 6 months. The AD and QL will be evaluated at the end of the intervention. As there are no dietary guidelines for RA, this study aims to provide scientific evidence about the impact of diet therapy on reducing AD and improving QL.
Detailed description
The main objective of this trial is to check the effect of an DAI, compared to a DC, on reducing AD and improving QL. As secondary objectives, it is intended to investigate the relationship of DAI with inflammatory markers and with the modulation of the composition / diversity of the intestinal microbiota, in comparison with a DC. This study combines all dietary components with an anti-inflammatory effect, thus allowing the possibility of evaluating the full potential of dietary treatment in the disease, including intestinal microbiota modulation. These results are intended to further contribute to clinical decision making and better evidence-based treatment.
Interventions
OTHERDiet Control
Diet following mediterranean principles, for 15 weeks
OTHERDiet anti-inflammatory
Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.
Sponsors
Hospital Particular do Algarve - HPA Saúde
Universidade Nova de Lisboa
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age over 18 years; * Presence of active disease, (DAS28≥ 2.6), under adequate control and medication. * Able to sign informed consent
Exclusion criteria
* Any type of psychological deficiency, dementia or eating disorder; * Presence of food allergies and / or intolerances; * Be vegetarian or use Phytotherapy or other supplements (namely, pre and probiotics); * Use of antibiotics im the last 6 months; * Have had previous nutritional monitoring or change in eating habits in the last 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in disease activity | 15 weeks | Difference between the intervention and control group in the changes in Disease Activity (using DAS28 score: greater than 2,6 implies active disease), from baseline to the end of follow-up |
| Changes in Quality of Life | 15 weeks | Difference between the intervention and control group in changes in Quality of Life (Health Assessment Questionnaire (HAQ): scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability), from baseline to the end of follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Rheumatoid Factor (RF) | 15 weeks | Difference between the intervention and control group changes in Rheumatoid Factor (RF) measured in IU/mL, from baseline to the end of follow-up |
| Changes in Gut microbiota | 15 weeks | Difference between the intervention and control group in the change of gut microbiota from baseline to the end of follow-up. Bacterial DNA will be extracted from fecal samples. 16SRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage. |
| Changes in C-Reactive Protein (CRP) | 15 weeks | Difference between the intervention and control group in changes in C-Reactive Protein (CRP) measured in mg/L, from baseline to the end of follow-up |
| Changes in Body Mass Index (BMI) | 15 weeks | Difference between the intervention and control group changes in BMI, calculated using weight and height, presented in kg/m2: underweight \< 18,5; normoweight 18,6-24,9; overweight 25-29,9; obese \>30, from baseline to the end of follow-up |
| Changes in waist circumference perimeter | 15 weeks | Difference between the intervention and control group changes in waist circumference perimeter, measured in cm, from baseline to the end of follow-up |
| Changes in weight | 15 weeks | Difference between the intervention and control group changes in weight, measured in Kg, from baseline to the end of follow-up |
| Changes in Erythrocyte Sedimentation Rate (ESR) | 15 weeks | Difference between the intervention and control group in changes in Erythrocyte Sedimentation Rate (ESR) measured in mm/h, from baseline to the end of follow-up |
Countries
Portugal
Outcome results
None listed